A study published in the Journal of Clinical Oncology found that pembrolizumab combined with chemotherapy improved disease-free survival in patients with high-risk endometrial cancer after curative surgery. The study focused on patients with mismatch repair-deficient tumors and showed that pembrolizumab significantly improved DFS compared to placebo. The two-year DFS rates were 92.4 percent for pembrolizumab and 80.2 percent for placebo. The researchers concluded that pembrolizumab plus chemotherapy is clinically relevant for patients with mismatch repair-deficient tumors in the curative-intent setting. The study was funded by Merck, the manufacturer of pembrolizumab.
Source link
Pembrolizumab aids survival with high-risk endometrial cancer
